Background: Targeting oncogenic genomic aberrations is an established therapeutic strategy in multiple tumor types. Molecular classification has uncovered a number of novel targets, and rapamycin-insensitive companion of mTOR (RICTOR) amplification has been identified in lung cancer. Further investigation assessing the therapeutic potential of RICTOR amplification as a novel target across advanced cancers is needed.
Introduction
The rapid expansion in the ability to interrogate the genome continues to identify putative oncogenic aberrations across tumor types [1] . Functional characterization is lacking in many genomic alterations and is important to refine the optimal therapeutic approach. Recently, rapamycin-insensitive companion of mTOR (RICTOR) amplification was identified by hybrid capture-based next-generation sequencing (NGS) in an 18-year-old neversmoker with lung adenocarcinoma who responded to mTORC1/ 2 inhibition [2] . The incidence of RICTOR amplification is 8-13% in lung cancer, and is a recurrent alteration across other tumor types represented in The Cancer Genome Atlas [2] . RICTOR is a key component of the PI3K/AKT/mTOR signal transduction pathway which is one of the most frequently altered pathways in cancer [3] . The mTOR pathway involves two signaling complexes: mTORC1 and mTORC2 [4] , and RICTOR is an essential component of the mTORC2 complex that is required for its full function [5, 6] . RICTOR up-regulation strengthens mTORC2 activity, which in turn promotes cell growth and motility [7] . Conversely, RICTOR down-regulation suppresses cell proliferation and tumor formation [8] [9] [10] . RICTOR also plays an essential role in the interplay between AKT and mTOR and is known as an important component of feedback loops and crosstalk in PI3K-AKT-mTOR signaling [11] [12] [13] [14] . Single agent PI3K inhibitors have been plagued my adaptive resistance mechanisms, but selective RICTOR-directed therapies have shown early promise in RICTOR-amplified lung cancer cell lines [2, 15] .
We sought to expand the therapeutic implications of RICTOR amplification (R-amp) using the large personalized cancer care program at Samsung Medical Center combining NGS-based tumor characterization and patient-derived cell lines. Our results suggest RICTOR amplification is a recurrent event in gastric cancer, and studies using an RICTOR-amp patient derived cell (PDC) line confirmed the increased sensitivity to dual mTORC1/2 inhibition. This study provides the first evidence of the therapeutic potential in targeting R-amp in gastric cancer, and supports pre-clinical and clinical investigation in other RICTOR amplified tumors.
Patients and methods

Methods-patients
Ethics statement. This investigation was conducted in accordance with the ethical standards of the Declaration of Helsinki and national and international guidelines, and was approved by the Institutional Review Board at Samsung Medical Center.
Patient studies. Between October 2013 and June 2015, 640 patients with gastrointestinal cancer, lung cancer, and rare cancers were prospectively enrolled in the VIKTORY trial (NCT#02299648) or the LUNG PERSEQ (NCT#02299622) trial at Samsung Medical Center, Seoul, Korea. Patient inclusion criteria were as follows; age !18 years, pathologically confirmed cancer, resection/biopsies of the primary or metastatic site, and available data on clinicopathologic characteristics. Patient tumor samples were collected for genomic sequencing and PDCs were established from patients in the VIKTORY trial willing to undergo fresh biopsy. Patients whose tumors harbored RICTOR amplification were identified from the trial database and clinicopathologic characteristics were abstracted.
Methods-materials
Genomic analysis. Formalin-fixed paraffin embedded (FFPE) samples containing >40% tumor cellularity were dissected under microscopy from 4-lm-thick unstained sections (10-20 slides) or from fresh frozen tissues by comparison with a hematoxylin and eosin-stained slide. Detailed method is provided in supplementary material.
Cell line studies. A PDC line was successfully cultured from a patient with RICTOR-amplified (NGS and FISH) advanced gastric cancer (AGC). Method for patient derived cell establishment is provided in sup plementary material.
RICTOR immunohistochemistry: RICTOR immunohistochemistry was performed using the primary RICTOR antibody (1:1000, ab70374, Abcam, Cambridge, MA). Formalin-fixed paraffin-embedded tumor samples were freshly cut to 4-lm thick sections and dried at 60 C for 30 min. Antigen retrieval was performed for 20 min using the LOW buffer (pH 6.0) in a 97 C water bath. Endogenous peroxidase blocking was conducted for 5 min. Samples were incubated with the primary antibody for 30 min in room temperature. Subsequently, the sections were incubated with Peroxidase/DAB-10 min K5007 from the DAKO Envision TM Detection Kit (DAKO, Glostrup, Denmark) for 30 min. The immunohistochemistry results were scored independently by two pathologists (HJB and KMK). The staining intensity (weak, moderate, and strong) and proportion of positive tumor cells were recorded.
Rictor fish: Tumor sections were cut to 1 lm thickness, followed by deparaffinization with the pretreatment reagent (Abbott, 30-801 250) at 80 C for 30 min. Protease digestion procedures were performed using the protease reagent (Abbott, 30-801 255) at 37 C for 20 min. RICTOR probes (Spectrum Orange Probe, RICTOR-20-RE) and Chromosome 5 control probe (Spectrum Green Probe, CHR5-10-GR) (Empire genomics, Michigan) were hybridized at 73 C for 5 min and 37 C for 20 h. After hybridization, the slides were washed in 2Â saline-sodium citrate/ 0.3% NP-40 at 72 C for 5 min, air dried, and counterstained with 4 0 ,6-diamidino-2-phenylindole (DAPI) II (Abbott Molecular, Illinois). The slides were examined under a fluorescence microscope equipped with Spectrum Texas Red with isothiocyanate and DAPI filters. The RICTOR/ Chr5 control ratio was established after counting at least 50 tumor cell nuclei. An RICTOR/Chr5 control ratio higher than 2.0 was interpreted as gene amplification-positive. RICTOR gene copy numbers more than 4 without gene amplification were interpreted as RICTOR polysomy.
Results
Patient characteristics
Between October 2013 and June 2015, we conducted genomic analysis on 640 solid tumor patients as part of the ongoing personalized cancer care program at Samsung Medical Center (NCT#02141152, NCT#02299622). Of the 640 patients, 13 patients (2%) had RICTOR-amplified tumors as determined by NGS with a cut-off value of !4.0 copies ( Table 1 ). The median age of the 13 patients was 62 years (range, 40-75 years) and the majority of patients were male (61.5%). Among RICTOR amplified samples the most common tumor-types were GC (46.2%) and non-small cell lung cancer (NSCLC) (23.0%), followed by small cell lung cancer (SCLC) (7.7%), colorectal cancer (7.7%), sarcoma (7.7%), and metastatic carcinoma of unknown origin (MUO) (7.7%). For GC, the overall prevalence of RICTOR amplification by NGS was 3.8% (6/160). NSCLC (3/118), SCLC (1/17), colorectal cancer (1/152) and sarcoma/rare cancer including MUO (2/73) were 2.5%, 5.8%, 0.7% and 2.7%, respectively.
FISH confirms RICTOR amplification detected by NGS
The 13 RICTOR-amplified tumor samples initially screened by the NGS platform were subjected to an orthogonal confirmatory FISH assay for RICTOR amplification. Among the 13 NGS-detected tumors, 5 cases, including 4 AGCs and 1 NSCLC, were found to have a RICTOR/control ratio of !2.0, indicating amplification of RICTOR by the FISH assay (Table 1) . A representative AGC sample with 25.86 copies of RICTOR determined by NGS and a RICTOR/CEP ratio of 12 is shown in Figure 1 . Concurrently, a PDC model was established from this patient and subjected to further experiments. The RICTOR amplification of this PDC line was further confirmed via qPCR (Figure 2A ).
RICTOR amplified PDC is sensitive to dual mTORC1/ 2 inhibition
To investigate differential effects of inhibiting key nodes in the canonical PI3K/AKT/mTOR pathway, we performed a cell viability assay using the RICTOR amplified gastric PDC line. MTT proliferation assays showed increased sensitivity to the dual mTORC1/ 2 inhibitor AZD2014 and the dual PI3K/mTOR compound BEZ235 ( Figure 2B ). Consistent with the functional importance of RICTOR amplification, everolimus, and the AKT inhibitor AZD5363 had lesser effects on growth of the PDC line and the multi-target kinase inhibitor pazopanib, did not suppress cell viability ( Figure 2B ). The IC 50 values of AZD5363, AZD2014, everolimus, and pazopanib are shown in Table 2 ; among the various inhibitors tested, AZD2014 showed the most potent inhibitory effect on RICTOR-amplified GC PDCs. As control, a non-RICTOR amplified GC PDC was unaffected by AZD2014 treatment ( Figure 2C ). AZD2014 was shown to potently suppress the phosphorylation of RICTOR, and the mTORC substrates S6, AKT, and mTOR but not cleaved casapase 3 ( Figure 2D ).
RICTOR knockdown confers resistance to AZD2014 effects
To better characterize the importance of RICTOR amplification on the observed AZD2014 growth inhibition we performed a shRNA-mediated RICTOR knockdown in the PDC model. As shown in Figure 2E , shRNAs effectively suppressed RICTOR expression in the RICTOR-amplified PDC model, and RICTOR knockdown was sufficient to abrogate the inhibitory effects of AZD2014 on cell growth. Additionally, growth rates of the untreated shRNA RICTOR knockdown were slower than the matched scrambled shRNA line (supplementary Figure S1 , available at Annals of Oncology online). Combined, this data supports the oncogenicity of RICTOR amplification and suggests highlevel amplification may be considered a "driver" event in AGC.
Discussion
Here we have demonstrated that RICTOR-amplification is a rare, but recurrent somatic alteration in solid tumors and provide preliminary evidence of therapeutic potential in RICTOR amplified advanced gastric cancer. The frequency of RICTOR amplification was 2.1% (13 of 640) among our patient cohort, and was mainly detected in GC, colorectal cancer, and lung cancer. This is largely consistent with pan-cancer analyses from the TCGA and suggests our NGS assay was sufficiently sensitive (Figure 3) .
The PI3K-AKT-mTOR pathway comprises complex connections with various feedback loops [16] [17] [18] [19] [20] . These characteristics can blunt the activity of each molecule resulting in the immediate resistance of single-target inhibitors against PI3K, AKT, and mTOR [15] . Mounting literature suggests that simultaneous combined inhibition of multiple nodes in the PI3K/AKT/mTOR pathway is more effective than targeting a single node, though may come at the expense of increased toxicity [21] [22] [23] [24] . Resistance to proximal PI3K pathway inhibition is commonly characterized by feedback AKT activation which has been linked to mechanisms involving the mTORC2 complex member RICTOR [22, [25] [26] [27] .
RICTOR has been associated with the up-and down-regulation of the PI3K-AKT-mTOR pathway through its role as a signal mediator between mTORC1 and mTORC2 [25, 26, 28] . RICTOR also interacts with integrin-linked kinase to promote cancer cell survival through AKT phosphorylation, and with protein kinase C to promote cancer cell invasion and metastasis [29, 30] . Targeting RICTOR was found to induce cell cycle arrest at the G1 phase and decrease cyclin D1 expression in breast, colon, and prostate cancer cells [9, 31] . Recently Cheng et al. tested six different PI3K-AKTmTOR inhibitors in RICTOR-amplified lung cancer cells, and found that agents blocking both mTORC1 and mTORC2 were the most active. In our study, we tested selective AKT, mTORC1, mTORC1/2, and multi-target tyrosine kinase-inhibitors in a RICTOR-amplified gastric PDC line and observed overall similar findings [2] . In our cell viability assay, the mTORC1/2 inhibitor AZD2014 revealed a more potent inhibitory effect against RICTOR-amplified PDCs compared to a more selective mTORC1 inhibitor or the multiple tyrosine kinase inhibitor pazopanib. This cross-cancer comparison suggests that RICTOR amplification serves an important oncogenic function independent of tumor type and genomic context. Consistent with a driver function, we did not observe concurrent ERBB2, PI3K/AKT/mTOR, or MAPK pathway alterations in our RICTOR amplified samples. Further work is needed to determine if our findings could be recapitulated with selective mTORC2 inhibition, suggesting that RICTOR amplification drives increased flux down mTORC2 mediated processes. The relative insensitivity to everolimus suggests this may be the case, though we cannot rule out typical IRS1-mediated resistance to everolimus [15] . One of the other potential marker of mTORC2 activation is mTOR-S2481p. We used AKT-S473 phosphorylation as a marker in this study. While we acknowledge that additional cell line experiments and PDC data would strengthen our data, the observation that the non-RICTOR amplified PDC was not sensitive ( Figure 2C ) and the shRNA data ( Figure 2E ) argue that response is indeed related to RICTOR amplification. Phosphorylation of AKT at serine 473 is a well-accepted substrate for mTORC2 and readout of inhibition [11, 32] and was used in several AZD2014 preclinical studies [33, 34] . As the ability of AZD2014 to inhibit mTORC1/2 is previously well reported and AKT p-S473 is an accepted mTORC2 readout we did not conduct the additional analyses including phosphorylation of mTOR at serine 2481. Further, antibodies directed against mTOR S2481 have sometimes been difficult to achieve reliable results and autophosphorylation at this site is also seen in mTORC1 [35] , and is more used as a marker of intact mTORC2 more than a major readout of inhibition.
Most studies targeting the mTOR pathway in cancer therapy have focused on rapamycin and its derivatives, which are relatively selective for mTORC1 over mTORC2. Preclinical studies have suggested that allosteric inhibition of mTOR by a rapalog inhibits only mTORC1 and leads to an increase in the phosphorylation of AKT due to feedback loops that allow for the continued activity of mTORC2 [28, 36, 37] . Consistent with this observation prior studies have shown more effective growth inhibition with more specific mTOR inhibitors [32, 38] .
The PI3K pathway is known to be recurrently altered in gastric cancer, but prior clinical studies in unselected patient populations, including the phase III GRANITE-1 trial (everolimus versus placebo), failed to improve patient outcomes (Figure 4 ) [39] . AZD2014 is a rationally designed ATP competitive mTORC1/2 inhibitor and has shown strong inhibitory activity across a range of in vitro and in vivo preclinical models [34] . Recently, phase I and phase II trials using AZD2014 have been conducted in patients with various tumor types [40, 41] . Although our analysis needs to be interpreted with caution due to small sample size, our PDC-derived data suggests RICTOR amplification may be a predictive and novel biomarker identifying a population with increased probability of responding to the dual mTORC1/2 inhibitor AZD2014.
An important finding from our study is the need for sensitive detection of uncommon alterations across tumor types. We used an NGS-based platform to screen for RICTOR amplification, and multiple other genomic alterations. Currently, FISH is considered a standard method for detecting gene amplification but is an expensive, time-consuming, and operator dependent process that can potentially exhaust tissue. There was a discrepancy between FISH results and NGS copy number results in our cohort. As the NGS-based platform becomes more validated in clinical samples, the necessity of FISH confirmation for NGS results is becoming less highlighted. Of 13 patients with RICTOR amplification by NGS, 5 had RICTOR protein overexpression by IHC, which further support the NGS results for RICTOR amplification. We stained for RICTOR expression and compared the results of IHC with those of the FISH assay (Table 1) . Among the five tumor samples with RICTOR amplification by FISH, all (4/4) of the GC samples also revealed positive RICTOR expression using IHC, however, one NSCLC sample did not. For external comparison we stained a random sample of 95 metastatic gastric cases from our dataset and performed RICTOR IHC as above and noted IHC expression in 17.9% of cases. Thus, within gastric cancer there was a 100% concordance between FISH and IHC in Ramp samples. However, given the established overall frequency of RICTOR IHC in GC screening with IHC is likely to require NGSvalidation to identify R-amp patients. Further studies are needed to investigate whether IHC is feasible to select RICTORamplified patients who might benefit from treatment with an mTORC1/2 inhibitor, the simultaneous information regarding other genomic alterations is an advantage of NGS over IHC.
While RICTOR has been investigated with descriptive studies in gastric cancer to our knowledge this is the first report of RICTOR amplified PDCs demonstrating selective sensitivity to dual mTOR inhibitors and provides compelling early information to justify ongoing pre-clinical and clinical investigation of AZD2014 in this molecular subgroup. It is established that genomic information is important in identifying patients for molecularly directed therapy, functional studies of uncommon pathogenic alterations are critical for advancing the precision medicine paradigm. Further work investigating other tumor types of varying genomic background and therapeutic combination approaches will continue to refine the optimal approach to RICTOR amplified tumor. For example, does a concurrent PIK3CA or KRAS mutation adversely affect the responsiveness to RICTOR-directed therapy? Based on our present study and other observations, AZD2014 is planned to enter into a clinical trial in RICTOR amplified GC.
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